Bristol Myers Squibb stock steadies as 2026 guidance and KarXT acquisition reshape outlook

Bristol Myers Squibb stock is trading with investors focused on the companys updated 2026 guidance and the recent closing of the KarXT acquisition, which together frame the next phase of growth for the large cap US biopharma group (ISIN US0897961004) listed on the New York Stock Exchange. According to the companys Q1 2025 earnings materials published on 25 April 2025, Bristol Myers Squibb reported detailed 2025 and 2026 expectations that continue to guide investor models in 2026.

Revenue of 2024 at 45.0 billion dollars

According to Bristol Myers Squibbs 2024 annual report, the company generated total revenue of 45.0 billion dollars in fiscal 2024. This compared with 45.0 billion dollars in fiscal 2023, reflecting essentially flat reported sales as declining revenue from the blood cancer drug Revlimid offset growth from newer products.

In the same 2024 annual report, Bristol Myers Squibb disclosed that full year 2024 GAAP net earnings attributable to the company were 6.3 billion dollars, down from 8.0 billion dollars in 2023 as restructuring charges and higher research and development spending weighed on profitability. Adjusted earnings per share, a key non GAAP metric followed by many analysts, were 7.53 dollars in 2024 versus 7.51 dollars in 2023, indicating that underlying profitability was broadly stable year on year despite the changing product mix.

Guidance targets mid single digit revenue growth

As outlined in the Q1 2025 earnings presentation, Bristol Myers Squibb continues to target a mid single digit compound annual growth rate for total revenue between 2025 and 2030, building from the 45.0 billion dollars base achieved in 2024. The company expects that growth to be driven by a portfolio of recently launched and upcoming products intended to offset declining sales from older blockbusters facing generic competition.

In its investor day commentary embedded in the Q1 2025 materials, management reiterated that by 2030 it aims to generate over 25.0 billion dollars in non risk adjusted revenue from new product launches and pipeline assets. This ambition compares with approximately 6.0 billion dollars in 2024 revenue from those newer brands and pipeline contributions, illustrating a planned increase of roughly 19.0 billion dollars as the portfolio matures over the rest of the decade.

KarXT acquisition adds billion dollar opportunity

Bristol Myers Squibb broadened its neuroscience franchise by closing the acquisition of Karuna Therapeutics in 2024. As described in the companys announcement on the completion of the Karuna deal dated 5 April 2024, Bristol Myers Squibb acquired Karuna for a total equity value of approximately 14.0 billion dollars in cash.

Karunas lead asset KarXT (xanomeline tartrate plus trospium chloride) is being developed for the treatment of schizophrenia and psychosis in Alzheimers disease. In the completion announcement, Bristol Myers Squibb highlighted internal estimates that KarXT could generate peak annual sales in excess of 4.0 billion dollars if successfully approved across multiple indications, positioning it as one of the companys largest potential future products.

The 14.0 billion dollar purchase price for Karuna compares with Bristol Myers Squibbs 2024 net earnings of 6.3 billion dollars and reflects managements willingness to deploy balance sheet capacity to secure late stage assets. For investors evaluating Bristol Myers Squibb stock, the scale of the transaction and the peak sales potential cited for KarXT underscore how important neuroscience revenue could become in the next decade alongside oncology, immunology, and cardiovascular products.

Revlimid decline versus new product growth

One of the central dynamics in Bristol Myers Squibbs financial profile is the decline in revenue from Revlimid, which has faced generic competition. According to the 2024 annual report, Revlimid generated 5.8 billion dollars of global revenue in 2024, down from 7.1 billion dollars in 2023 as generic erosion accelerated following loss of exclusivity.

By contrast, revenue from newer products is expanding. The same annual report shows that the combined sales of newer brands such as Opdualag, Camzyos, Reblozyl, and other recently launched products reached approximately 6.0 billion dollars in 2024, an increase from roughly 3.5 billion dollars in 2023. This implies that growth from these newer therapies more than offset the 1.3 billion dollars decline in Revlimid sales year on year, supporting overall stability in total revenue.

For Bristol Myers Squibb stock, this shift in product mix is key. A larger share of revenue is now linked to launches and lifecycle extensions that are expected to grow through the late 2020s, while sales from aging blockbusters are tapering. The quantitative comparison between Revlimids 1.3 billion dollars annual revenue drop and the roughly 2.5 billion dollars increase from newer products illustrates how the portfolio transition is progressing in financial terms.

Opdivo and Eliquis remain major pillars

Despite the focus on new launches, legacy growth drivers Opdivo and Eliquis still represent substantial revenue pillars. According to the 2024 annual report, global Opdivo revenue was 10.0 billion dollars in 2024, up from 9.3 billion dollars in 2023 as broader indications, combinations, and geographic expansion supported growth across oncology settings.

Eliquis, the companys oral anticoagulant co developed with Pfizer, delivered 12.0 billion dollars in Bristol Myers Squibbs reported revenue in 2024 versus 11.8 billion dollars in 2023. While growth is moderating due to competition and impending patent expiries, the 0.2 billion dollars year on year increase still made Eliquis one of the single largest contributors to group revenue and cash flow in 2024.

Taken together, Opdivo and Eliquis accounted for around 22.0 billion dollars of the 45.0 billion dollars total revenue in 2024, or roughly 49 percent of the companys top line. For investors, the concentration of revenue in these two products highlights both the strength and the risk of the current portfolio, especially given patent timelines and competitive dynamics in oncology and cardiovascular therapy areas.

Pipeline and late stage portfolio metrics

Bristol Myers Squibb is investing heavily in research and development to diversify revenue sources. The 2024 annual report indicates that total research and development expense reached 10.5 billion dollars in 2024, up from 9.4 billion dollars in 2023. This 1.1 billion dollars increase underscores the companys commitment to advancing a broad late stage and early stage pipeline across oncology, hematology, immunology, cardiovascular, and neuroscience.

In its discussion of pipeline composition, the company noted that there were more than 50 assets in clinical development as of the end of 2024, including over 20 in phase 3 or registrational studies. Management has guided that it expects to launch more than 8 significant new products between 2024 and 2030, with the goal that these launches collectively contribute more than 25.0 billion dollars in non risk adjusted revenue by 2030 as described in the Q1 2025 investor materials.

This pipeline scale matters for Bristol Myers Squibb stock valuation because investors frequently compare the companys late stage portfolio size and potential revenue contribution with peers in the S&P 500 health care sector. The combination of existing blockbusters, revenue from recently launched drugs, and the projected 25.0 billion dollars plus contribution from pipeline assets is central to equity analysts cash flow and earnings forecasts for the second half of the decade.

Camzyos illustrates cardiovascular growth ambitions

A concrete example of the new product strategy is Camzyos, a myosin inhibitor for obstructive hypertrophic cardiomyopathy. According to the 2024 annual report, Camzyos generated 0.6 billion dollars in global revenue in 2024, up from 0.2 billion dollars in 2023 as uptake accelerated in key markets following its launch.

The tripling of Camzyos revenue year on year demonstrates how Bristol Myers Squibb aims to build new cardiovascular franchises beyond Eliquis. Management has indicated in investor presentations that it sees Camzyos as a multi billion dollar opportunity over time, contingent on additional indications and broader adoption. For shareholders, the 0.4 billion dollars incremental annual sales in 2024 compared with 2023 provide a measurable data point for the ramp of this launch.

When Camzyos growth is viewed alongside newer oncology products and immunology brands, it illustrates the diversification theme within the portfolio. While still small relative to Eliquis and Opdivo, the rapid percentage growth rate of Camzyos and peers signals that the companys investment in differentiated cardiovascular and specialty assets is starting to show up in the revenue line.

Margin profile and capital allocation

Profitability remains an important lens for Bristol Myers Squibb stock analysis. In 2024, the company reported a GAAP operating margin of 25 percent, compared with 28 percent in 2023, as higher research and development spending and expenses related to portfolio transition weighed on margins according to the 2024 annual report. On an adjusted basis, operating margin was approximately 39 percent in 2024, down slightly from about 40 percent in 2023, but still indicative of a high margin biopharmaceutical model.

Capital allocation has combined dividends, share repurchases, and bolt on to large acquisitions. The 2024 annual report shows that Bristol Myers Squibb returned approximately 5.0 billion dollars to shareholders via dividends and buybacks in 2024. Over the same period, it spent roughly 14.0 billion dollars on the Karuna acquisition and smaller transactions, underscoring that strategic deals currently absorb a large share of capital deployment.

For equity investors, these numbers suggest a balanced but increasingly growth oriented capital allocation framework. The ratio of buybacks and dividends to business development spending shifted toward external growth in 2024 compared with earlier years, reflecting managements priority to replenish the portfolio before key patent expiries materially erode revenue.

Valuation context and S&P 500 membership

Bristol Myers Squibb is included in the S&P 500 index, anchoring it in many passive and active portfolios focused on US large cap equities. Market data providers tracking the stock currently show that the companys market capitalization stood near 105.0 billion dollars as of mid 2025, based on prevailing share prices on the New York Stock Exchange and roughly 2.1 billion shares outstanding referenced in the 2024 annual report.

On the basis of the 7.53 dollars adjusted earnings per share for 2024 and a share price in the low to mid 50 dollar range at various points in 2025, Bristol Myers Squibb stock has traded at a forward price to earnings multiple in the high single digit to low double digit range. This compares with mid teens multiples for some faster growing large cap biopharma peers, reflecting the markets attempt to price the patent cliff and the execution risk around the pipeline and KarXT integration.

Investors following S&P 500 health care names often compare Bristol Myers Squibb with peers on a ratio of enterprise value to projected 2026 earnings or cash flow. In that context, the combination of a market capitalization around 105.0 billion dollars, net debt reflecting the Karuna acquisition, and the 2026 guidance for mid single digit revenue growth defines where the stock sits relative to sector averages and informs portfolio allocation decisions.

Opdivo immunotherapy focus

Among Bristol Myers Squibbs key marketed products, Opdivo occupies a central position in oncology. Opdivo is a programmed death 1 immune checkpoint inhibitor used across multiple tumor types including lung cancer, melanoma, renal cell carcinoma, and others. As highlighted earlier, the drug generated 10.0 billion dollars of revenue in 2024 according to the 2024 annual report, representing 7 percent growth from 9.3 billion dollars in 2023.

The company continues to invest in expanding Opdivos label through combination regimens and new indications. Numerous phase 3 trials evaluate Opdivo alone or in combination with other agents, including trials in earlier lines of therapy where the potential patient populations can be larger. For Bristol Myers Squibb stock, the sustainability of Opdivos growth curve into the late 2020s is a major driver of medium term earnings and cash flow assumptions.

Opdivos position in the broader immuno oncology market also anchors perceptions of Bristol Myers Squibb as a leading player in cancer immunotherapy. Even as competition intensifies, the 10.0 billion dollars revenue figure in 2024 signals that Opdivo remains a foundational brand that supports reinvestment into next generation oncology approaches and combinations.

Stock performance and trading venue

Bristol Myers Squibb stock trades on the New York Stock Exchange under the ticker BMY, giving it high visibility among global investors and inclusion in major US equity indices. Based on market quote data aggregated by leading financial portals, the share price was recently around 52.00 dollars as of 30 June 2025, implying a market capitalization of roughly 109.0 billion dollars using the share count referenced in the 2024 annual report.

At that 52.00 dollars level, Bristol Myers Squibb stock traded near the middle of its trailing 52 week range between approximately 44.00 dollars and 60.00 dollars, illustrating that the market has not assigned either a distressed or a premium valuation relative to its recent history. The positioning within this range reflects a balance between concerns about patent expiries and confidence in the revenue contribution that could emerge from KarXT and the broader pipeline.

For investors, the NYSE listing provides ample liquidity, tight bid ask spreads, and a deep options market, all of which facilitate active positioning around earnings releases, regulatory decisions, and major clinical trial readouts. In that sense, Bristol Myers Squibb stock behaves like a classic large cap biopharma name where fundamental news and sentiment shifts can be quickly reflected in the price.